Rua Bioscience Income Statement

Financials in millions NZD. Fiscal year is July - June.

Millions NZD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	2.15	1.51	0.09	0.36	0.02	-
Other Revenue	0.24	0.32	0.23	0.31	0.62	0.36
Revenue	2.39	1.83	0.32	0.67	0.65	0.36
Revenue Growth (YoY)	124.84%	477.39%	-52.68%	3.63%	79.53%	-
Cost of Revenue	1.39	0.98	0.2	0.34	0.13	-
Gross Profit	1	0.85	0.11	0.33	0.52	0.36
Research & Development	0.98	0.94	1.18	1.59	2.98	1.9
Other Operating Expenses	3.42	3.24	3.55	5.18	5.12	4.74
Operating Expenses	4.4	4.18	4.73	6.77	8.1	6.64
Operating Income	-3.39	-3.33	-4.62	-6.44	-7.58	-6.28
Interest Expense	-0.29	-0.16	-0.02	-0.02	-0.04	-0.03
Interest & Investment Income	0	0	0.13	0.2	0.14	0.05
Currency Exchange Gain (Loss)	-	-	0	-	-	-
EBT Excluding Unusual Items	-3.68	-3.49	-4.51	-6.25	-7.49	-6.27
Impairment of Goodwill	-	-	-8.25	-	-	-
Gain (Loss) on Sale of Assets	0.03	0.03	-0.53	-	0	-
Asset Writedown	0.01	-	-0.43	-5.57	-	-
Other Unusual Items	0.19	0	-	5.86	-	0.09
Pretax Income	-3.45	-3.46	-13.72	-5.96	-7.49	-6.17
Income Tax Expense	-	-	-	0	1.15	-1.76
Net Income	-3.45	-3.46	-13.72	-5.96	-8.64	-4.42
Net Income to Common	-3.45	-3.46	-13.72	-5.96	-8.64	-4.42
Shares Outstanding (Basic)	262	195	158	154	144	127
Shares Outstanding (Diluted)	262	195	158	154	144	127
Shares Change (YoY)	62.31%	23.01%	2.95%	6.63%	13.17%	30.68%
EPS (Basic)	-0.01	-0.02	-0.09	-0.04	-0.06	-0.03
EPS (Diluted)	-0.01	-0.02	-0.09	-0.04	-0.06	-0.03
Free Cash Flow	-2.37	-2.79	-3.74	-5.99	-7.25	-5.85
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.04	-0.05	-0.05
Gross Margin	41.88%	46.54%	35.47%	49.21%	80.06%	100.00%
Operating Margin	-141.84%	-182.57%	-1459.98%	-962.92%	-1175.69%	-1748.19%
Profit Margin	-144.06%	-189.19%	-4336.57%	-891.46%	-1338.73%	-1229.48%
Free Cash Flow Margin	-98.98%	-152.79%	-1181.50%	-896.65%	-1123.09%	-1627.85%
EBITDA	-3.05	-3	-4.28	-5.85	-6.94	-5.69
EBITDA Margin	-127.63%	-164.01%	-	-	-	-
D&A For EBITDA	0.34	0.34	0.34	0.58	0.64	0.6
EBIT	-3.39	-3.33	-4.62	-6.44	-7.58	-6.28
EBIT Margin	-141.84%	-182.57%	-	-	-	-
Revenue as Reported	2.47	1.9	0.32	6.53	0.65	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.